We are live on ! Find out more
KYTX icon

Kyverna Therapeutics

99 hedge funds and large institutions have $321M invested in Kyverna Therapeutics in 2025 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 9

135% more capital invested

Capital invested by funds: $136M → $321M (+$184M)

100% more funds holding in top 10

Funds holding in top 10: 36 (+3)

38% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 21

32% more funds holding

Funds holding: 7599 (+24)

25.45% more ownership

Funds ownership: 52.48%77.93% (+25%)

19% less call options, than puts

Call options by funds: $967K | Put options by funds: $1.19M

Holders
99
Holders Change
+24
Holders Change %
+32%
% of All Funds
1.2%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.07%
New
36
Increased
29
Reduced
21
Closed
9
Calls
$967K
Puts
$1.19M
Net Calls
-$227K
Net Calls Change
-$1.29M
Name Holding Trade Value Shares
Change
Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$1.93M +$541K +72,816 +55%
UBS Group
27
UBS Group
Switzerland
$1.9M +$332K +44,765 +28%
BGM
28
Burkehill Global Management
New York
$1.88M +$1.48M +200,000 New
MIM
29
Monashee Investment Management
Massachusetts
$1.83M +$1.45M +195,000 New
SAM
30
Simplify Asset Management
Nevada
$1.81M +$1.43M +192,339 New
PLC
31
Peapod Lane Capital
New York
$1.73M -$1M -134,940 -42%
Jane Street
32
Jane Street
New York
$1.71M -$124K -16,758 -8%
Renaissance Technologies
33
Renaissance Technologies
New York
$1.67M +$98.6K +13,285 +8%
BCM
34
Bridgeway Capital Management
Texas
$1.64M
Barclays
35
Barclays
United Kingdom
$1.55M +$657K +88,477 +116%
MS
36
Maven Securities
Jersey
$1.38M +$1.09M +146,400 New
Squarepoint
37
Squarepoint
New York
$1.31M +$1.03M +138,868 New
Marshall Wace
38
Marshall Wace
United Kingdom
$1.27M +$1.01M +135,600 New
Manulife (Manufacturers Life Insurance)
39
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.26M +$228K +30,722 +30%
Goldman Sachs
40
Goldman Sachs
New York
$1.26M +$671K +90,398 +210%
Stifel Financial
41
Stifel Financial
Missouri
$1.18M +$646K +86,969 +224%
Charles Schwab
42
Charles Schwab
California
$1.18M -$1.13K -152 -0.1%
6CM
43
683 Capital Management
New York
$1.08M +$853K +114,900 New
KCP
44
Kera Capital Partners
California
$1.06M -$2.15M -289,321 -69%
Jacobs Levy Equity Management
45
Jacobs Levy Equity Management
New Jersey
$1.02M -$291K -39,178 -27%
State Street
46
State Street
Massachusetts
$858K
Hudson Bay Capital Management
47
Hudson Bay Capital Management
Connecticut
$832K +$657K +88,553 New
JF
48
Jump Financial
Illinois
$755K +$596K +80,299 New
Dimensional Fund Advisors
49
Dimensional Fund Advisors
Texas
$737K +$582K +78,413 New
Wells Fargo
50
Wells Fargo
California
$705K +$421K +56,669 +310%

KYTX Hedge Fund Activity: Q4 2025 in Review

99 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q4 2025, worth a combined $321M — up 135% from $136M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new KYTX positions and 9 closed out — a net gain of 27 holders — while 29 added to existing stakes and 21 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $14.8M. The largest seller was Franklin Resources, exiting entirely with an estimated $4.07M sold.

  • 99 institutional investors held Kyverna Therapeutics (KYTX) as of Q4 2025, up from 75 in Q3 2025.
  • Funds reported $321M of Kyverna Therapeutics stock for Q4 2025, up 135% quarter-over-quarter.
  • 36 funds opened new Kyverna Therapeutics positions in Q4 2025 and 9 closed out, a net change of +27 holders.
  • The largest Kyverna Therapeutics buyer in Q4 2025 was Deerfield Management, an estimated $14.8M added.
  • The largest Kyverna Therapeutics seller in Q4 2025 was Franklin Resources, an estimated $4.07M sold.

Based on aggregated 13F filings for Q4 2025.